Chimeric Protein for Hypercholesterolemia via Intramuscular Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current genetic transfer technologies for treating genetic disorders, such as hypercholesterolaemia, face challenges in achieving stable and long-lasting metabolic effects with safe and efficient chimeric protein production, particularly due to toxicity concerns and immune responses associated with viral vector administration.
Innovation Solution
Development of a human or murine chimeric protein expressed by a viral vector, specifically a fusion protein combining the low-density lipoprotein receptor and transferrin sequences, for intra-muscular administration using a helper-dependent adenoviral vector, which reduces systemic risks and enhances muscle-specific expression.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If viral vectors are administered for hepatic expression of therapeutic transgenes, then cholesterol levels can be reduced, but toxicity and immune response increase making the approach unsafe for clinical use
Solution Approach 1:
The patent uses an adenoviral vector as an intermediary delivery system that carries the chimeric protein gene to muscle tissue rather than directly to the liver. This intermediary approach allows the therapeutic protein to be produced in a safer location (muscle) that still achieves systemic cholesterol reduction while minimizing direct hepatic toxicity and immune response
Solution Approach 2:
The patent creates a chimeric protein that copies the essential functional domains of the LDL receptor (ligand binding domain and transmembrane domain) while fusing them to a Fc region, enabling the protein to perform LDL cholesterol clearance function without requiring direct modification of hepatic cells, thus achieving therapeutic effect through a simplified, safer molecular copy
2Reliability
If ex vivo genic therapy is attempted with retroviral vectors, then feasibility and safety of genic therapy can be confirmed, but stable and long-lasting metabolic effects are not achieved
Solution Approach 1:
The patent changes the key parameter of delivery route from ex vivo hepatic transduction to in vivo intramuscular injection of viral vectors. This parameter change enables sustained expression of the chimeric protein in muscle tissue, which continuously secretes the therapeutic protein into circulation, achieving both safety confirmation and long-lasting metabolic effects
3Quantity of substance
If endovenous administration of viral vectors is used for hepatic expression, then cholesterol levels can be lowered, but the approach creates potential toxicity that prevents clinical use
Solution Approach 1:
The patent shifts the therapeutic approach from a two-dimensional hepatic delivery system (endovenous injection → liver) to a three-dimensional systemic approach (intramuscular injection → muscle expression → secretion into bloodstream → systemic circulation). This dimensional change allows the therapeutic protein to reach all tissues including the liver indirectly, achieving cholesterol reduction while avoiding direct hepatic toxicity
Data Source
AI summary
A human chimeric protein(1) is described, expressed by a viral vector (2) designed for treating patients affected by genetic disorders, composed of a first cDNA sequence [SEQ. 2] of a N-terminal extracellular portion of a human receptor (4) of low-density lipoproteins (5) (hLDLR), fused with a second cDNA sequence [SEQ. 3] of the human transferrin (7) (hTf).